Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator initiated phase 2b/3 pivotal trial for OmnImmune in treatment of acute myeloid leukemia

Next Previous
Trial Profile

An investigator initiated phase 2b/3 pivotal trial for OmnImmune in treatment of acute myeloid leukemia

Status: Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 19 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TCB 002 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ACHIEVE-2

Most Recent Events

  • 13 Nov 2023 According to a TC BioPharm media release, company expects to propose amendments to ACHIEVE 2 protocols in dosing and other areas in an effort to generate a more heterogeneous data set across trials.
  • 13 Nov 2023 According to a TC BioPharm media release, company will continue dosing patients for the phase 2B clinical trial beginning in 2024, with an additional 14 patients to be dosed prior to an interim look at data.
  • 07 Feb 2023 According to a TC BioPharm media release, the company announced the official dosing of its final patient from the safety cohort for ACHIEVE, its phase 2B clinical trial of OmnImmune (TCB008); Pending the final review of the Data Safety Monitoring Board (DSMB), the Company will move to open enrolment of the trial, and expect a positive formal review from the DSMB in February; TC BioPharm will report additional results as they become available.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top